Table 2.
Comparisons of clinical features and laboratory findings by different thyroid dysfunction identification.
| Normal Thyroid | Subclinical hypothyroidism | Hypothyroidism | Euthyroid sick syndrome | P | |||
|---|---|---|---|---|---|---|---|
| Low T3 | Low T4 | Low T3T4 | |||||
| Clinical characteristics | |||||||
| N | 57 | 61 | 83 | 66 | 5 | 45 | — |
| Age (Year) | 41.3 ± 14.33 | 41.72 ± 15.44 | 38.24 ± 16.79 | 42.92 ± 15.9 | 41.4 ± 16.3 | 40.33 ± 16.65 | 0.604 |
| Male (%) | 54.4% | 62.3% | 49.4% | 50.0% | 60.0% | 53.3% | 0.714 |
| Duration of NS (Month) | 6.00 [1.00, 10.00] | 4.00 [1.00, 7.00] | 2.00 [1.00, 8.00] | 3.00 [1.00, 8.00] | 3.00 [2.00, 6.00] | 2.00 [1.00, 7.75] | 0.210 |
| PRO (g/24 h) | 4.03 ± 2.45 | 6.51 ± 4.33 | 9.71 ± 7.42* | 6.71 ± 4.9 | 7.26 ± 5.22 | 10.85 ± 8.62* | <0.001 |
| PCR (g/mmol Cr) | 0.47 ± 0.4 | 0.79 ± 0.51 | 1.01 ± 0.58* | 0.76 ± 0.53 | 0.76 ± 0.37 | 1.02 ± 0.8* | <0.001 |
| ALB (g/L) | 28.68 ± 6.19 | 24.19 ± 5.65* | 19.01 ± 4.56* | 25.52 ± 6.11* | 22.88 ± 4.96 | 19.48 ± 3.99* | <0.001 |
| SCR (umol/L) | 61.50 [55.00, 75.00] | 68.00 [56.00, 84.30] | 69.00 [53.00, 94.70] | 73.80 [52.60, 119.00]* | 54.00 [53.00, 67.00] | 79.90 [59.35, 138.30]* | <0.001 |
| TG (mmol/L) | 354.36 ± 87.87 | 366.4 ± 101.97 | 343.16 ± 81.35 | 372.28 ± 123.63 | 346.66 ± 97.66 | 373.26 ± 105.08 | 0.525 |
| TC (mmol/L) | 2.03 ± 1.06 | 2.5 ± 1.51 | 2.53 ± 1.8 | 2.14 ± 1.18 | 1.83 ± 0.63 | 2.83 ± 1.88* | 0.062 |
| LDL (mmol/L) | 7.15 ± 2.24 | 8.14 ± 2.96 | 9.37 ± 3.11 | 7.19 ± 2.98* | 6.86 ± 1.84 | 9.44 ± 3.66* | <0.001 |
| FT3 (pmol/L) | 4.54 ± 1.93 | 5.3 ± 2.5 | 6.27 ± 2.69* | 4.44 ± 2.41 | 4.33 ± 1.2 | 6.31 ± 3.38* | <0.001 |
| TT3 (nmol/L) | 4.49 ± 0.64 | 4.31 ± 1 | 2.76 ± 0.71* | 3.11 ± 1.9* | 3.95 ± 0.47 | 2.28 ± 0.89* | <0.001 |
| FT4 (pmol/L) | 1.64 ± 0.26 | 1.61 ± 0.43 | 1.08 ± 0.27 | 1.14 ± 0.35 | 2.04 ± 0.2 | 0.93 ± 0.36 | <0.001 |
| TT4 (nmol/L) | 15.8 ± 2.18 | 14.7 ± 3.02 | 11.05 ± 2.68* | 14.61 ± 2.32* | 10.74 ± 1.07* | 10.34 ± 1.42* | <0.001 |
| TSH (mU/L) | 87.32 ± 12.8 | 84.87 ± 19.35 | 49.72 ± 16.71 | 86.53 ± 24.48 | 83.51 ± 1.2 | 48.85 ± 9.67 | <0.001 |
| RT3 (nmol/L) | 2.98 [2.05, 3.60] | 6.25 [5.1, 7.16] | 6.98 [5.54, 9.04] | 2.6 [1.50, 3.15] | 3.23 [2.00, 3.27] | 2.45 [1.67, 3.09] | <0.001 |
| PRO(g/24 h) | 0.36 ± 0.14 | 0.33 ± 0.12 | 0.25 ± 0.15 | 0.32 ± 0.11 | 0.28 ± 0 | 0.36 ± 0.16 | 0.214 |
| HB (g/L) | 143.14 ± 23.55 | 134.44 ± 26.16 | 135.7 ± 22.89 | 123.95 ± 26.87* | 134.6 ± 11.44 | 133.8 ± 24.84 | 0.002 |
| WBC (10^9/L) | 7.36 ± 2.53 | 7.87 ± 2.92 | 7.47 ± 2.66 | 8.12 ± 3.72 | 6.19 ± 3 | 9.13 ± 4.25* | 0.045 |
| PLT (10^9/L) | 202.23 ± 72.02 | 237.98 ± 97.93 | 241.43 ± 76.58* | 213.26 ± 90.17 | 214.6 ± 29.06 | 241.98 ± 88.11 | 0.043 |
| Coexisting diseases (%) | |||||||
| Hypertension | 17.5% | 26.2% | 10.8% | 27.3% | 20.0% | 17.8% | 0.120 |
| Diabetes | 1.8% | 6.6% | 1.2% | 10.6% | 0.0% | 6.7% | 0.086 |
| Pulmonary infection | 7.0% | 6.6% | 16.9%* | 15.2%* | 0.0% | 24.4%* | 0.040 |
| AKI | 1.8% | 0.0% | 4.8% | 4.5% | 0.0% | 8.9% | 0.127 |
| CKD | 1.8% | 4.9% | 3.6% | 12.1% | 0.0% | 13.3% | 0.058 |
| Renal biopsy (%) | |||||||
| MCD | 28.1% | 21.7% | 48.8% | 33.3% | 20.0% | 38.6% | <0.001 |
| MPGN | 3.5% | 1.7% | 1.2% | 0.0% | 0.0% | 6.8% | |
| MsPGN | 0.0% | 1.7% | 2.4% | 4.8% | 0.0% | 6.8% | |
| MN | 40.4% | 46.7% | 22.0% | 23.8% | 0.0% | 27.3% | |
| FSGS | 3.5% | 5.0% | 1.2% | 3.2% | 80.0% | 6.8% | |
| IgAN | 10.5% | 10.0% | 6.1% | 11.1% | 0.0% | 4.5% | |
| Secondary NS | 10.9% | 11.3% | 14.9% | 22.0% | 0.0% | 8.6% | |
Data are expressed as mean ± standard deviation, median and interquartile range, or percent frequency, as appropriate.
MN membranous nephropathy, MCD minimal-change disease, FSGS focal segmental glomerulosclerosis, MPGN membrane proliferative glomerulonephritis, MsPGN mesangial proliferative glomerulonephritis, secondary secondary reasons of nephrotic syndrome.
*P < 0.05, Comparison versus normal thyroid group.